10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

SFTPC Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP13684b

Specification

SFTPC Antibody (C-term) Blocking peptide - Product Information

Primary Accession P11686

SFTPC Antibody (C-term) Blocking peptide - Additional Information

Gene ID 6440

Other Names
Pulmonary surfactant-associated protein C, SP-C, Pulmonary surfactant-associated proteolipid SPL(Val), SP5, SFTPC, SFTP2

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13684b was selected from the C-term region of SFTPC. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SFTPC Antibody (C-term) Blocking peptide - Protein Information

Name SFTPC

Synonyms SFTP2

Function
Pulmonary surfactant associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces.

Cellular Location
Secreted, extracellular space, surface film.

SFTPC Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

SFTPC Antibody (C-term) Blocking peptide - Images

SFTPC Antibody (C-term) Blocking peptide - Background

This gene encodes the pulmonary-associated surfactantprotein C (SPC), an extremely hydrophobic surfactant proteinessential for lung function and homeostasis after birth. Pulmonarysurfactant is a surface-active lipoprotein complex composed of 90%lipids and 10% proteins which include plasma proteins andapolipoproteins SPA, SPB, SPC and SPD. The surfactant is secretedby the alveolar cells of the lung and maintains the stability ofpulmonary tissue by reducing the surface tension of fluids thatcoat the lung. Multiple mutations in this gene have beenidentified, which cause pulmonary surfactant metabolism dysfunctiontype 2, also called pulmonary alveolar proteinosis due tosurfactant protein C deficiency, and are associated withinterstitial lung disease in older infants, children, and adults.Alternatively spliced transcript variants encoding differentprotein isoforms have been identified.

SFTPC Antibody (C-term) Blocking peptide - References

Wambach, J.A., et al. Pediatr. Res. 68(3):216-220(2010)Schuurhof, A., et al. Pediatr. Pulmonol. 45(6):608-613(2010)Thouvenin, G., et al. Arch. Dis. Child. 95(6):449-454(2010)Crossno, P.F., et al. Chest 137(4):969-973(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)